MedPath

Intermittent Low Energy Diet in CKD: MIX UP Feasibility Study

Not Applicable
Completed
Conditions
Chronic Kidney Diseases
Obesity
Interventions
Behavioral: Renal Weight Management Programme
Registration Number
NCT03736551
Lead Sponsor
King's College Hospital NHS Trust
Brief Summary

This study proposes to investigate the acceptability and efficacy of intermittent VLED (5:2 diet) plus exercise, compared with the investigator's established Weight Management Programme (WMP), in obese patients with CKD, using feasibility study methodology.

Patients will be invited to participate in the parallel arm, single blinded, randomised controlled feasibility study, and randomly allocated to 1 of 2 treatments for 6 months. The experimental arm involves an intermittent modified fasting regimen consisting of VLED (600 kcal/day) on 2 consecutive days, and 5 days each week on a modified diet to maintain an overall energy deficit of 600 kcal/day across the week (5:2 diet). The control arm will be the standard renal WMP with a continuous energy restricted diet aimed at reducing daily energy intake by 600 kcal/day.

The feasibility outcomes are: recruitment rate \>50%; intervention retention rate at 6 months \>60%; dietary intervention compliance; and weight loss. Secondary outcomes include safety, body composition, proteinuria, lipids, blood pressure, and eating desire. Measurements will be made at baseline, midpoint, and twice at endpoint.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
13
Inclusion Criteria
  • aged 18-75 years
  • KDIGO defined CKD (all categories)
  • BMI ≥30kg/m2
  • able to provide written informed consent in English
Exclusion Criteria
  • pregnant or breastfeeding women
  • conservatively managed CKD stage 5
  • palliative or active treatment for cancer
  • unstable chronic liver disease
  • type 1 diabetes and type 2 diabetes controlled with anti-hyperglycaemic medication
  • previous bariatric surgery
  • unable to provide written informed consent
  • significant psychiatric disorder or uncontrolled depression
  • participated in a weight management drug trial in the previous 3 months
  • uncontrolled epilepsy
  • alcohol or substance abuse

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
InterventionRenal Weight Management ProgrammeThe intervention arm will involve standard care plus an intermittent modified fasting regimen consisting of a very low energy diet (600 kcal/day) on 2 consecutive days of the week, and 5 days each week on an energy restricted diet to maintain a similar overall energy deficit of 600 kcal/day across the week (5:2 diet). All dietary intake on modified fasting days will be from LighterLife foodpacks, (4 x 150 kcal portions/day presented as milkshakes, cereal bars, soups and modified meals such as spaghetti bolognese, or macaroni cheese) providing \~600 kcal/day and 100% of the RNI for vitamins and minerals.
Standard CareRenal Weight Management ProgrammeRenal Weight management Programme - Patients will attend individual appointments with the specialist dietitian and physiotherapist once a month, for 6 months. Dietary intervention includes a standard continuous energy restricted diet aimed at reducing daily energy intake by 600 kcal/day relative to their estimated total energy expenditure (9). In addition to the dietary intervention, the programme also includes personal exercise plans, optional pharmacotherapy (orlistat at standard dose), and development of personalised dietary and exercise goals using behavioural therapy techniques and motivational interviewing.
Primary Outcome Measures
NameTimeMethod
Number of Adverse Events following intermittent very low energy diet6 months

record of all adverse events including but not limited to nausea, constipation and/or diarrhoea, dehydration, hypoglycaemia, lethargy \& fatigue, headaches, gallstones and gout.

Retention rate of at least 60% in the intervention group6 months

Patients attending at least 80% of monthly clinic visits, including the baseline and final study visits, and remaining compliant with the 2 consecutive days VLED throughout the 6 month intervention will be considered "completers" and count as being retained in the intervention group at 6 months.

Secondary Outcome Measures
NameTimeMethod
HDL cholesterol6 months

plasma HDL cholesterol concentration

Compliance with dietary intervention from dietary records6 months

at least 70% compliance with prescribed diet

Body composition6 months

lean and fat mass (kg) estimated by bioelectrical impedance analysis

LDL cholesterol6 months

plasma LDL cholesterol concentration

Recruitment rate of at least 50% of potential participants meeting inclusion and exclusion criteria1 year

at least 50% of those meeting the referral criteria and are approached to participant, consent to participating in the study

Waist circumference (cm)6 months

change in waist circumference measured in cm at level of umbilicus

Exercise capacity - sit to stand 606 months

number (count) of sit to stand movements in 60 seconds

Proteinuria6 months

urinary protein to creatinine ratio

Triglycerides6 months

plasma triglycerides concentration

Weight change (kg)6 months

change in weight from baseline to 6 months

Total Cholesterol6 months

plasma total cholesterol concentration

kidney function (eGFR ml/min CKD EPI equation)6 months

monitoring if estimated kidney function declines during the study or if symptomatic for dehydration.

Exercise capacity - 6 minute timed walk test6 months

distance walked (m) in 6 minutes

Trial Locations

Locations (1)

King's College Hospital

🇬🇧

London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath